tldrdailynews.com logo
Tag

Viking Therapeutics

All articles tagged with #viking therapeutics

Viking Therapeutics Emerges as a Possible M&A Target in Obesity Space After Vertex-Crinetics Pact
business13 days ago

Viking Therapeutics Emerges as a Possible M&A Target in Obesity Space After Vertex-Crinetics Pact

Vertex’s about $10 billion Crinetics acquisition has rekindled takeover chatter in the obesity-drug space, putting Viking Therapeutics (VKTX) in the spotlight as a potential target. Viking’s VK2735 is advancing in the late-stage VANQUISH trials with injectable and planned oral forms, while VK3019 has entered Phase 1, adding a second asset targeting obesity and metabolic disorders. Although attractive to large pharma seeking diversified portfolios, Viking remains a clinical-stage company with no revenue, so any deal would depend on forthcoming VK2735 and VK3019 data and the company’s cash runway.

via Yahoo Finance|
#business#manda#obesity
Viking Therapeutics Shares Drop Over 30% Amidst Obesity Trial Setbacks
business11 months ago

Viking Therapeutics Shares Drop Over 30% Amidst Obesity Trial Setbacks

Viking Therapeutics' stock dropped 37% after revealing that its obesity drug VK2735 had a high dropout rate in a Phase 2 trial, despite showing some efficacy in weight loss. The high discontinuation rate raised concerns about the drug's tolerability and competitive position compared to Eli Lilly's offerings, leading to investor skepticism about Viking's prospects in the oral obesity market.

via Yahoo Finance|
#business#dropout-rate#obesity-trial
Trump Era Set to Ignite M&A Surge, Wall Street Anticipates
business1 year ago

Trump Era Set to Ignite M&A Surge, Wall Street Anticipates

With Donald Trump returning to the presidency and Republicans controlling Congress, a less stringent regulatory environment could lead to a surge in mergers and acquisitions (M&A). Factors like recent interest rate cuts and potential changes in the Federal Trade Commission's leadership could further encourage M&A activity. Viking Therapeutics, a clinical-stage pharmaceutical company with promising obesity treatments, is highlighted as a potential acquisition target, though any such deals remain speculative.

via The Motley Fool|
#business#interest-rates#mergers-and-acquisitions
"Viking Therapeutics' Weight-Loss Pill Shows Promising Phase 1 Results, Stocks Soar"
businesshealthcare2 years ago

"Viking Therapeutics' Weight-Loss Pill Shows Promising Phase 1 Results, Stocks Soar"

Viking Therapeutics' stock surged over 25% after reporting positive Phase 1 results for its oral weight-loss drug, showing up to 5.3% weight loss in patients with minimal side effects. The company plans to launch the drug into Phase 2 trials later this year, following strong results from its injectable version. Analysts view the data as a "clear win" and believe the drug has best-in-class potential, positioning it to compete with current market leaders in the weight-loss drug space.

via Yahoo Finance|
#businesshealthcare#oral-glp-1-option#phase-1-results
"Analysts Laud Viking Therapeutics' Soaring Stock on Positive Weight-Loss Drug Data"
finance2 years ago

"Analysts Laud Viking Therapeutics' Soaring Stock on Positive Weight-Loss Drug Data"

Viking Therapeutics stock surged by 25% after announcing positive results from a phase 1 clinical study of its oral obesity drug VK2735, showing up to 3.3% placebo-adjusted mean weight loss and promising safety and tolerability. The company plans to advance the oral and injectable formulations of the drug into further testing, with expectations for strong pipeline prospects, making it a potential buy for aggressive investors.

via Yahoo Finance|
#finance#obesity-drug#phase-1-clinical-study
"Viking Therapeutics' Oral Weight-Loss Drug Shows Promise in Phase 1 Study"
health-and-pharmaceuticals2 years ago

"Viking Therapeutics' Oral Weight-Loss Drug Shows Promise in Phase 1 Study"

Viking Therapeutics' experimental weight-loss tablet, VK2735, showed promising results in a small early-stage trial, with the highest 40-milligram dose leading to a 3.3% weight loss in participants. The company's shares rose 15% following the news. Viking plans to continue testing higher doses and expects to initiate a mid-stage study in obese patients later this year. The drug's oral version could offer a more convenient option for patients, especially those who have achieved significant weight loss with the injectable version.

via Yahoo Finance|
#clinical-trial#health-and-pharmaceuticals#obesity
"Viking Therapeutics' Oral Weight-Loss Pill Demonstrates Positive Phase 1 Study Results"
health-and-pharmaceuticals2 years ago

"Viking Therapeutics' Oral Weight-Loss Pill Demonstrates Positive Phase 1 Study Results"

Viking Therapeutics' stock surged over 15% after positive results from a small study on its experimental weight loss pill, which is set to enter the next stage of development later this year. The once-a-day oral tablet showed promising results in reducing weight, with patients losing up to 5.3% of their weight on average. The company plans to start a phase two trial for the pill and believes that treating patients beyond 28 days may lead to further reductions in body weight. Analysts view Viking as a strong potential player in the burgeoning weight loss drug market, which could grow into a $100 billion market by the end of the decade.

via CNBC|
#biotech#clinical-trial#health-and-pharmaceuticals
"Viking Therapeutics' Oral Weight Loss Pill Shows Promising Results in Clinical Trial"
health2 years ago

"Viking Therapeutics' Oral Weight Loss Pill Shows Promising Results in Clinical Trial"

Viking Therapeutics announces positive results from a Phase 1 clinical trial of VK2735, a dual GLP-1/GIP receptor agonist, showing up to 3.3% placebo-adjusted mean weight loss and low rates of gastrointestinal adverse events after 28 days of oral tablet formulation. The company plans to initiate a Phase 2 trial in obesity later this year and will host a conference call to discuss the results. VK2735 demonstrated promising early weight loss and tolerability, with potential for additional weight loss with longer treatment duration and higher doses.

via PR Newswire|
#glp-1gip-receptor-agonist#health#obesity
"Comparing Weight Loss Drugs: Viking Therapeutics vs. Eli Lilly's GLP-1"
finance2 years ago

"Comparing Weight Loss Drugs: Viking Therapeutics vs. Eli Lilly's GLP-1"

Eli Lilly, a pharmaceutical giant, has a strong track record of success with a lineup of approved medicines and impressive financial results, including the potential blockbuster drug tirzepatide. On the other hand, Viking Therapeutics, a clinical-stage biotech company, has shown promise with positive phase 2 results for its potential weight loss drug VK2735 and has another candidate for non-alcoholic steatohepatitis. While Eli Lilly offers stability and proven success, Viking Therapeutics presents a higher risk but with potential for significant returns.

via Yahoo Finance|
#biotech#eli-lilly#finance